

Xenon Genetics Incorporated

[View the current Xenon Genetics Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/bioporporate/11092-Xenon+Genetics+Incorporated.html)

(<http://www.bioportfolio.com/bioporporate/11092-Xenon+Genetics+Incorporated.html>)

Contact Details:

650 Gilmore Way

Burnaby

British Columbia

V5G 4W8

Canada

Tel: 604-484-3300

Fax: 604-484-3450

Email: info@xenongenetics.com

Xenon Genetics is a privately owned, genomics-based drug discovery and development company engaged in identifying genes and other drug targets associated with human disease and developing pharmaceutical therapies based on these genetically-derived targets. Xenon has multiple drug discovery programs in three therapeutic areas: cardiovascular, metabolic and neurological diseases. Each of these areas represents a substantial opportunity for the development of new, more effective therapies targeting unmet clinical needs.

Recent Publications by Xenon Genetics Incorporated:



- [Identification of a novel gene \(HSN2\) causing hereditary sensory and autonomic neuropathy type II through the Study of Canadian Genetic Isolates.](#)
Hereditary sensory and autonomic neuropathy (HSAN) type II is an autosomal... 4th June, 2004
Xenon Genetics Research, Xenon Genetics Inc., Burnaby, British Columbia- *Am J Hum Genet.* 2004 May;74(5):1064-73. Epub 2004 Apr 1. ([DOI Direct Link](#))

Press Releases on Xenon Genetics Incorporated:

Reportlinker Adds Blood Banking and Blood Products - Global Market Perspective	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Blood Banking and Blood Products - Global Market Perspective http://www
Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference	24th November, 2009	Quest Diagnostics	MADISON, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is
Prodesse's ProParaflu+(TM) Assay Cleared for US Marketing by FDA	24th November, 2009	Gen-Probe Incorporated	Michael Watts Vice president, investor relations and corporate communications 858-410-8673 SOURCE Gen-Probe Incorporated
deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal	24th November, 2009	deCODE Genetics Inc	REYKJAVIK, Iceland, November 24 /PRNewswire-FirstCall/ -- deCODE genetics, Inc. (Nasdaq:DCGN) today announced that it has received notice from the Nasdaq Stock Market that trading in the company
deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court	24th November, 2009	DeCODE Genetics Inc	REYKJAVIK, Iceland, November 24 /PRNewswire-FirstCall/ -- deCODE genetics, Inc. (Nasdaq:DCGN) today announced the approval of all of its "first day" motions by the U.S. Bankruptcy Court

Xenon Genetics Incorporated Patents:



- 7256028- [Methods for screening compounds that modulate lipid metabolism](#)
- 7166584- [Cholesterol transport gene](#)
- 6759208- [High throughput screening assays using fatty acid synthetic enzymes](#)

- 6617122- [Process for identifying modulators of ABC1 activity](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

